Ovid Therapeutics Inc.
OVID · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $2 | $208 |
| % Growth | 44.4% | -73.9% | -99.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $0 | $2 | $208 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $37 | $29 | $25 | $47 |
| G&A Expenses | $26 | $30 | $32 | $37 |
| SG&A Expenses | $26 | $30 | $32 | $37 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $2 | $0 | $0 |
| Operating Expenses | $62 | $60 | $57 | $84 |
| Operating Income | -$62 | -$59 | -$56 | $124 |
| % Margin | -10,933.7% | -15,122.7% | -3,696.4% | 59.6% |
| Other Income/Exp. Net | $35 | $7 | $1 | -$0 |
| Pre-Tax Income | -$26 | -$52 | -$54 | $124 |
| Tax Expense | $0 | $0 | $0 | $1 |
| Net Income | -$26 | -$52 | -$54 | $123 |
| % Margin | -4,670.1% | -13,351.8% | -3,604.7% | 58.9% |
| EPS | -0.37 | -0.74 | -0.77 | 1.78 |
| % Growth | 50% | 3.9% | -143.3% | – |
| EPS Diluted | -0.37 | -0.74 | -0.77 | 1.76 |
| Weighted Avg Shares Out | 71 | 71 | 70 | 67 |
| Weighted Avg Shares Out Dil | 71 | 71 | 70 | 68 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $5 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $0 |
| EBITDA | -$58 | -$57 | -$54 | $124 |
| % Margin | -10,207.1% | -14,544.1% | -3,604.5% | 59.7% |